15,000 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Acquired by Erste Asset Management GmbH

Erste Asset Management GmbH bought a new stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 15,000 shares of the company’s stock, valued at approximately $741,000.

Several other large investors also recently added to or reduced their stakes in MLTX. FMR LLC raised its holdings in shares of MoonLake Immunotherapeutics by 35.8% during the 3rd quarter. FMR LLC now owns 4,950,224 shares of the company’s stock valued at $249,590,000 after purchasing an additional 1,306,215 shares in the last quarter. Avoro Capital Advisors LLC lifted its position in shares of MoonLake Immunotherapeutics by 7.4% in the second quarter. Avoro Capital Advisors LLC now owns 2,770,000 shares of the company’s stock worth $121,797,000 after buying an additional 190,000 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in shares of MoonLake Immunotherapeutics by 4.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,167,358 shares of the company’s stock worth $58,858,000 after acquiring an additional 49,733 shares in the last quarter. Federated Hermes Inc. increased its holdings in shares of MoonLake Immunotherapeutics by 2.6% during the 2nd quarter. Federated Hermes Inc. now owns 1,128,428 shares of the company’s stock valued at $49,617,000 after acquiring an additional 28,672 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in shares of MoonLake Immunotherapeutics by 115.0% in the 2nd quarter. Marshall Wace LLP now owns 1,098,630 shares of the company’s stock valued at $48,307,000 after acquiring an additional 587,684 shares in the last quarter. 93.85% of the stock is owned by institutional investors.

Insider Activity

In other MoonLake Immunotherapeutics news, Director Simon Sturge sold 171,000 shares of the stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $53.72, for a total transaction of $9,186,120.00. Following the sale, the director now owns 171,980 shares of the company’s stock, valued at $9,238,765.60. This represents a 49.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.02% of the stock is currently owned by corporate insiders.

MoonLake Immunotherapeutics Trading Down 7.5 %

Shares of MoonLake Immunotherapeutics stock opened at $51.30 on Wednesday. The stock has a market capitalization of $3.28 billion, a price-to-earnings ratio of -39.77 and a beta of 1.31. The firm’s 50-day moving average price is $50.21 and its two-hundred day moving average price is $46.65. MoonLake Immunotherapeutics has a 1-year low of $37.55 and a 1-year high of $64.98.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12). During the same quarter in the previous year, the business earned ($0.18) earnings per share. As a group, equities research analysts predict that MoonLake Immunotherapeutics will post -1.74 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on MLTX shares. Wedbush restated an “outperform” rating and issued a $73.00 price objective (down from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of MoonLake Immunotherapeutics in a report on Thursday, November 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of MoonLake Immunotherapeutics in a research report on Monday, September 23rd. Needham & Company LLC reaffirmed a “buy” rating and set a $62.00 target price on shares of MoonLake Immunotherapeutics in a research report on Thursday, September 12th. Finally, Wolfe Research downgraded shares of MoonLake Immunotherapeutics from an “outperform” rating to a “peer perform” rating in a report on Monday, August 26th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $79.00.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.